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The development of pharmacological magnetic resonance imaging (phMRI) has presented the oppor-
tunity for investigation of the neurophysiological effects of drugs in vivo. Psilocin, a hallucinogen
metabolised from psilocybin, was recently reported to evoke brain region-speciﬁc, phMRI signal changes
in humans. The present study investigated the effects of psilocin in a rat model using phMRI and then
probed the relationship between neuronal and haemodynamic responses using a multimodal mea-
surement preparation. Psilocin (2 mg/kg or 0.03 mg/kg i.v.) or vehicle was administered to rats (N ¼ 6/
group) during either phMRI scanning or concurrent imaging of cortical blood ﬂow and recording of local
ﬁeld potentials. Compared to vehicle controls psilocin (2 mg/kg) evoked phMRI signal increases in a
number of regions including olfactory and limbic areas and elements of the visual system. PhMRI signal
decreases were seen in other regions including somatosensory and motor cortices. Investigation of
neurovascular coupling revealed that whilst neuronal responses (local ﬁeld potentials) to sensory stimuli
were decreased in amplitude by psilocin administration, concurrently measured haemodynamic re-
sponses (cerebral blood ﬂow) were enhanced. The present ﬁndings show that psilocin evoked region-
speciﬁc changes in phMRI signals in the rat, conﬁrming recent human data. However, the results also
suggest that the haemodynamic signal changes underlying phMRI responses reﬂect changes in both
neuronal activity and neurovascular coupling. This highlights the importance of understanding the
neurovascular effects of pharmacological manipulations for interpreting haemodynamic neuroimaging
data.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Pharmacological MRI (phMRI) offers the opportunity for in vivo
characterisation of the neurophysiological effects of drugs on the
brain. As such, it is becoming an increasingly important tool in basiclood oxygen level dependent;
LC, locus coeruleus; LFP, local
ion of interest; SSRI, selective
n), c.howarth@shefﬁeld.ac.uk
k (A.A. Khrapitchev), trevor.
logy.ox.ac.uk (N.R. Sibson), c.
r Ltd. This is an open access articlresearch, drug discovery and development (Borsook et al., 2006;
Murphy and Mackay, 2011; Wise and Tracey, 2006), and in
research studies involving clinical populations (Fleisher et al., 2009;
Mukherjee et al., 2014; Reynell and Harris, 2013). As it is a tech-
nique that can be deployed in both human and experimental ani-
mal research paradigms, phMRI is also ﬁnding an important
translational role in neuropsychopharmacological research (Couch
et al., 2013; Schwarz et al., 2007). This approach has recently been
applied to psilocybin, the active constituent of “magic” mush-
rooms; which is of interest due to its potential utility in treating
affective disorders (Carhart-Harris et al., 2012a, 2012b; Grob et al.,
2011; Vollenweider and Kometer, 2010).
Psilocybin, similar to other hallucinogenic agents, is an agonist
at the serotonin 2A (5-HT2A) receptor, which is the primary medi-
ator of its hallucinogenic effects (Quednow et al., 2012;e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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relevant to its therapeutic effects is unclear. It also shows afﬁnity for
all other serotonin receptors, with the exception of 5-HT3
(Halberstadt and Geyer, 2011). 5-HT2A receptor agonism is known
to modulate pyramidal cell activity in the prefrontal cortex and
anterior cingulate cortex, areas implicated in affective disorders
(Vollenweider and Kometer, 2010). Positron emission tomography
(PET) studies in humans show changes in cerebral glucose meta-
bolism in the anterior cingulate cortex as well as in other frontal
areas associated with cognitive changes following psilocybin
administration (Gouzoulis-Mayfrank et al., 1999; Vollenweider
et al., 1997) while widespread decreases in cerebral blood ﬂow
(CBF) and phMRI signals have been observed (Carhart-Harris et al.,
2012a).
Findings such as those described above are potentially impor-
tant for guiding the development of therapeutic drugs, as well as
for reﬁning our understanding of brain disease. However, inter-
pretation of phMRI data is not straightforward, as the haemody-
namic changes uponwhich the imaging signals depend, such as the
BOLD response, are not a direct measure of neuronal activity, but
rather rely on the relationship between haemodynamic changes
and the underlying neuronal activity (Logothetis, 2008). In phar-
macological neuroimaging, this relationship, known as neuro-
vascular coupling, may be affected by both the pharmacological
manipulations themselves and/or by resultant alterations in
neurotransmission (Martin and Sibson, 2008). This means that
phMRI studies cannot solely be interpreted in terms of the effects of
the drug of interest upon neurons.
In the case of psilocybin, whilst the pronounced phMRI signal
decreases observed could be interpreted as evidence of neuronal
deactivation (Carhart-Harris et al., 2012a), the physiological
mechanisms producing decreased phMRI signals, and their rela-
tionship to neuronal activity remains unclear. Indeed, such pro-
cesses may be highly dependent on differences between
anatomical regions, and local synaptic input, as well as a number of
factors (Kim and Ogawa, 2012; Lauritzen et al., 2012).
In vivo, psilocybin undergoes ﬁrst pass metabolism to psilocin,
the active metabolite thought to account for most of the psycho-
tropic effects of psilocybin administration (Hasler et al., 1997;
Passie et al., 2002). A further potential confound in interpretation
of BOLD signals in the case of psilocin is the combined neuronal and
vascular effects of serotonergic drugs (Cohen et al., 1996; Fukuda
et al., 2002). The 5-HT2A receptor has vasoconstrictive effects
(Kovacs et al., 2012; Martin, 1994), and psilocin also has afﬁnity for
the 5-HT1D and 5-HT1B receptors (Halberstadt and Geyer, 2011),
which have both neuronal and vascular effects (Gupta and Villalon,
2010; Kovacs et al., 2012). Additionally, serotonergic innervation of
the cerebrovasculature may result in vascular effects of serotonin
drugs that are separate from their direct actions on neuronal re-
ceptors (Hamel, 2006).
In experimental animal models, it is possible to combine
neuronal recordings with simultaneous measurement of haemo-
dynamics in order to better characterise the source of the negative
BOLD signal and investigate in ﬁne detail the coupling between
neuronal and haemodynamic signal changes (Boorman et al., 2010).
Evidence suggests negative BOLD signals can have separable hae-
modynamic (Devor et al., 2005; Harel et al., 2002) and neuronal
(Shmuel et al., 2006) sources and may occur in the presence of
increased neuronal signalling (Angenstein et al., 2009). Further-
more, in cases where negative BOLD signals are associated with
reduced neuronal responses it is difﬁcult in a phMRI paradigm to
distinguish between direct drug effects and the effects of activation
of inhibitory interneurons (Shih et al., 2009). In summary, a more
detailed understanding of haemodynamic-based neuroimaging
signals in the context of pharmacological manipulations isimportant for the continued application of phMRI techniques in
human subjects.
The aim of this study was to determine the effects of pharma-
cological manipulation of serotonergic neurotransmission by psi-
locin on the relationship between neuronal activity and the
haemodynamic responses that underpin neuroimaging signal
changes. We used a rodent model in which we combined whole
brain phMRI measures of drug action with determination of neu-
rovascular coupling relationships by concurrent measurement of
neuronal activity and cerebral blood ﬂow changes in response to
sensory stimulation.
2. Materials and methods
2.1. Animals and experimental design
Male SpragueeDawley rats (Charles River, UK) weighing
213e381 g were used. Animals were housed under a 12:12 h light/
dark cycle, with food and water available ad libitum. All experi-
ments were carried out in accordance with the UK Animals (Sci-
entiﬁc Procedures) Act (1986) under a U.K. Home Ofﬁce licence.
Eighteen Animals were used for phMRI data acquisition,
comprising vehicle control, low-dose and high-dose groups (N ¼ 6
per group). A further 12 animals were used for concurrent cerebral
blood ﬂow and neuronal activity measures, comprising drug and
vehicle control groups (N ¼ 6 per group) in a repeated measures
design (pre and post-drug stimulation and data acquisition
epochs).
2.2. Surgical procedures
Animals were anaesthetised with 4e5% isoﬂurane in a 30:70
mixture of oxygen and nitrogen, and maintained on 2e3% iso-
ﬂurane for the duration of surgical procedures. Animals were tra-
cheotomised and the femoral vein and artery cannulated. To record
cerebral blood ﬂow, high resolution laser speckle contrast imaging
was conducted. The animal's head was ﬁxed in a stereotaxic frame
and a window in the cranium was thinned over the left somato-
sensory cortex. To record neuronal activity, a burr hole was drilled
in the rostrolateral corner of the thinned cranial window and a
recording electrode was inserted to a depth of 0.5 mm. Following
surgery, animals were maintained on 1.5% isoﬂurane anaesthesia
for the remainder of the experiment. At the end of all experiments,
animals were killed by overdose with pentobarbital or trans-
cardially perfused under terminal anaesthesia.
2.3. Drugs
Psilocin (Lipomed, Arlesheim, Switzerland and Tocris, Abingdon,
UK) was dissolved in 0.05 mM tartaric acid vehicle and 1N sodium
hydroxide used to raise the pH to 5e7. Final concentrations were
1 mg/mL, for injections at a dose of 2 mg/kg, and 0.075 mg/mL for
injections at a dose of 0.03 mg/kg.
2.4. Functional MRI experiments
Functional MRI acquisitions were carried out on a 9.4 T hori-
zontal bore MRI system (Agilent Technologies, UK) using a 72 mm
volume coil (InsightMRI, Worcester MA, USA; m2m Imaging,
Cleveland OH, USA and RAPID Biomedical, Rimpar, Germany).
Datasets of 26 horizontal slices to cover the whole brain were ac-
quired using a T2*-weighted multi-echo gradient-echo sequence
with the following parameters: ﬂip angle ¼ 15; matrix
size ¼ 96  96; relaxation time (TR) ¼ 625 ms; echo time
(TE)¼ 3e18ms (6 echos, 3 ms apart); slice thickness¼ 0.5mm. One
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acquired before i.v. administration of psilocin (2 mg/kg or 0.03 mg/
kg) or vehicle (N ¼ 6/group), and imaging continued for 45 min
after drug administration. Arterial blood gases were sampled
before and after imaging.
2.5. Cerebral blood ﬂow and neuronal activity measurements
The laser speckle contrast imager (FLPI-2, Moor Instruments,
Axminster, UK; 785 nm laser diode; 576  768 pixel greyscale CCD
image capture) was positioned above the thinned cranial window
and blood ﬂow was imaged at 25 Hz and recorded using moorFLPI
Measurement v3.0 (Moor Instruments, UK). Local ﬁeld potentials
(LFPs) were simultaneously acquired from the implanted electrode
(0.155 mm diameter, Teﬂon insulated platinum; Bilaney Consul-
tants Ltd., Sevenoaks, UK), sampled at 10 kHz using an isolated
ampliﬁer unit coupled to a data acquisition device (systems 1902
and 1401, Cambridge Electronic Design, Cambridge, UK), and
recorded using a PC running Spike2 software (Cambridge Electronic
Design, UK), which also controlled stimulus delivery. There was a
minimum 45 min delay before the start of recordings to avoid the
inﬂuence of cortical spreading depression effects following elec-
trode implantation.
2.6. Stimulation protocol
Prior to administration of 2 mg/kg psilocin or vehicle (N ¼ 6/
group) animals underwent 10 whisker pad stimulation trains of
16 s duration, with a 60 s inter-stimulus-interval (ISI), at a fre-
quency of 10 Hz. Following this, 60 stimulation trains of 2 s dura-
tion, with a 25 s ISI, at frequencies of 1, 2, 5, 10, 20 and 40 Hz were
carried out. The order of stimulus frequencies was pseudorando-
mised. In all cases the amplitude of the stimulus was 1.2mA and the
stimulation pulse width was 0.3 ms. Subsequently, four 30 s
duration episodes of hypercapnia (10% CO2) were induced, with an
interval of 3 min between the start of each episode. After drug
administration the stimulation and hypercapnia paradigms were
repeated as before.
2.7. Data analysis
fMRI data were averaged across echoes prior to analysis in order
to increase the contrast-to-noise ratio. Data were analysed using
FEAT (FMRI Expert Analysis Tool) Version 5.92, part of FMRIB's
Software Library (FSL, www.fmrib.ox.ac.uk/fsl; Jenkinson et al.,
2012). For analysis of individual animals, data were smoothed,
the time of drug administration used as a regressor in the general
linear model with the scan registered to a standard template
(Schweinhardt et al., 2003). Activated voxels were identiﬁed using a
cluster thresholding method (Worsley et al., 1992) with a z-score
threshold of 2.3 and cluster signiﬁcance level of 0.05. Individual
animal analyses were combined for higher level analysis using a
ﬁxed effects model to compare the effects of the two doses of
psilocin to placebo, and to generate mean change in BOLD activa-
tion for each group. Regions of interest (ROIs) for time series
extraction were deﬁned as areas showing signiﬁcant BOLD signal
change in animals that received 2 mg/kg psilocin within the
following anatomical ROIs based on the changes in human subjects
seen in Carhart-Harris et al., (2012a); the hypothalamus, amygdala
and cingulate cortex. The somatosensory cortex was also included.
Extracted time series were normalised to the baseline 15 min of
pre-drug administration scanning and averaged in 5 min bins.
Processing of laser speckle and LFP data was carried out using
custom-written code in Matlab (2013a), and SPSS 21 was used for
statistical analysis. Laser speckle data were downsampled to 5 Hz.For CBF value changes in response to whisker stimulation, statis-
tical parametric mapping was used to identify a responsive ROI.
Time series data from this regionwere extracted and normalised to
a 10 s baseline period preceding each stimulation train to give
percentage changes in cerebral blood ﬂow. The area under the
curve (AUC) and maximum for each response were calculated.
Where stimulation trains were of 16 s duration, both early (0e8 s
after stimulation onset) and late (10e20 s after stimulation onset)
response maxima were identiﬁed. The response maxima for each
animal (pre- and post-drug treatment) were divided by the pre-
drug maxima to give a measure of fractional change in response
magnitude. Statistical comparisons were made using multifactorial
ANOVA where pre- and post-drug administration, drug type and
stimulation frequency (where applicable) were used as factors.
For analysis of data from hypercapnic challenge, the entire
thinned skull area was used as an ROI and the extracted CBF data
were normalised to a 25 s baseline prior to the onset of each CO2
challenge. Data were normalised as for whisker stimulation ex-
periments and smoothed using a SavitskyeGolay ﬁlter. Statistical
comparisons were by two-way ANOVA, where pre- and post-drug
administration and drug type were used as factors and a p value
of less than 0.05 was considered signiﬁcant.
In electrophysiological recordings the stimulation artefact was
removed from the LFP response to each pulse in each stimulation
episode. The stimulation artefact was replaced by a straight line
vector containing the same number of points as the stimulation
artefact and connecting the last point before and the ﬁrst point
after the artefact. The baseline of the response to each stimulation
train was set to zero by subtracting the mean calculated over
100 ms prior to stimulation onset. Data were band-pass ﬁltered
(pass between 17.36 Hz and 2604.25 Hz) to remove low and high
frequency noise. To quantify neuronal response magnitudes, the
AUC was calculated for each pulse in the stimulation train (over a
20.5 ms period following stimulation onset) and values were
summed over the stimulation train. Statistical comparisons were
made as for the CBF responses to stimulation.
One animal in the vehicle-treated group was excluded from
these analyses as it showed a maximal CBF response to stimulation
before drug administration that was more than eleven standard
deviations greater than the mean maximum response seen in other
animals in the group.
3. Results
3.1. Functional MRI
Psilocin, at a dose of 2 mg/kg, produced a mixed pattern of
positive and negative BOLD signal changes throughout the brain
compared to vehicle treated controls. A summary of the regions
showing signal changes is presented in Table 1. At a dose of
0.03 mg/kg psilocin produced a small BOLD signal decrease in the
cerebellum compared to vehicle treated controls but had no effect
in other regions. Consequently, experiments carrying out concur-
rent measurement of neuronal activity and CBF changes used psi-
locin at a dose of 2 mg/kg for pharmacological manipulation.
Time series extracted from regions showing signiﬁcant BOLD
signal changes demonstrated decreases in BOLD signal in the
cingulate cortex and somatosensory cortex after drug administra-
tion in animals receiving 2mg/kg psilocin (Figs. 1A and C; 2A, E, D&
H), but an increased BOLD signal in the hypothalamus and amyg-
dala (Figs.1B; 2B, F, C&G). Whole brain activationmaps for animals
that received psilocin at a dose of 2 mg/kg are shown in
Supplementary Figs. 1 and 2. A NIFTI format raw brain image from a
representative animal in the vehicle control group is also provided
in the Supplementary materials for this paper.
Fig. 1. At a dose of 2 mg/kg psilocin produced BOLD signal decreases in the cingulate
cortex compared to vehicle treated controls while a dose of 0.03 mg/kg produced no
change (A). Signal decreases were also observed at a dose of 2 mg/kg in the somato-
sensory cortex (C). The same dose produced signal increases in the amygdala and
hypothalamus while a dose of 0.03 mg/kg produced no change in the same regions (B).
All experimental groups have N ¼ 6.
Table 1
Anatomical regions showing BOLD signal changes following administration of 2 mg/
kg psilocin.
Increased BOLD signal vs vehicle Decreased BOLD signal vs vehicle
Olfactory and limbic areas Prelimbic cortex
Amygdalar nuclei Cingulate cortex
Olfactory tubercle Primary motor cortex
Piriform cortex Secondary motor cortex
Endopiriform nucleus Somatosensory cortex
Substantia nigra, pars reticulata Barrel cortex
Optic tract Thalamic nuclei
Hypothalamic nuclei Dorsal lateral geniculate nucleus
Hippocampus Lateral posterior thalamic nucleus
Dentate gyrus Dorsolateral periaqueductal grey
Subiculum Superior colliculus
Presubiculum Entorhinal cortex
Cerebral peduncle Hippocampus
Pontine nuclei CA3
Gigantocellular reticular nucleus CA1
Paramedian reticular nucleus Fimbria
Lateral and medial habenulae
Visual cortex
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Psilocin treated animals showed increased haemodynamic
response amplitude to whisker stimulation following drug
administration (Fig. 3A). There was a signiﬁcant effect of drug
treatment on the amplitude of the initial (0e8 s from stimulation
onset) part of the CBF response to long, 16 s duration, 10 Hz stim-
ulation and a signiﬁcant interaction between this effect and pre-/
post-drug administration. There was a signiﬁcant effect of pre-/
post-drug administration on this measure (statistics summarised in
Table 2). There were no signiﬁcant effects on the maximum of the
second part of the response (10e20 s from stimulation onset; sta-
tistics summarised in Table 2).
Maximum CBF responses tomixed frequency (1e40 Hz) whisker
stimulations of short, 2 s duration did not differ according to drug
treatment or pre-/post-drug administration and no signiﬁcant ef-
fect of whisker stimulation frequency on response maxima was
found (Fig. 3C, statistics summarised in Table 3). In order to
investigate whether the effects observed with a longer (16 s
duration) stimulation (see above) were replicated for this speciﬁc
frequency (10 Hz) in the short stimulation condition, a separate
two-way ANOVA was run using only data for the 2 s, 10 Hz stimuli.
This showed a signiﬁcant effect of drug treatment and a signiﬁcant
interaction effect of drug treatment with pre-/post-drug adminis-
tration on maximum CBF response to whisker stimulation (Table 3,
bottom row). Speciﬁcally, psilocin treated animals showed a greater
maximum CBF response after receiving drug treatment (Fig. 3C) in
agreement with the data from the 16 s stimulation condition. Re-
sults of equivalent analyses for the other ﬁve stimulation fre-
quencies and statistics are shown in Supplementary Table S1.
No effects of drug treatment were evident on the latency of the
haemodynamic responses to either long, 16 s duration, or short
mixed-frequency whisker stimulation (statistics shown in Table 2).
There were no signiﬁcant differences between the maximal CBF
responses of vehicle and psilocin treated animals to 30 s of hy-
percapnia (statistics shown in Table 4).3.3. Neuronal responses to somatosensory stimulation
Neuronal responses in the long, 16 s whisker stimulation con-
dition, as determined by the AUC of LFP responses, were not
signiﬁcantly altered by drug treatment condition (see Figs. 3B and
4; statistics summarised in Table 5).In contrast, in the short, mixed frequency stimulation condition,
psilocin treated animals showed a signiﬁcant reduction in neuronal
response magnitude (Fig. 3D). The drug type  pre-/post-drug
administration  stimulation frequency interaction effect was sig-
niﬁcant. There was also a signiﬁcant interaction between drug type
and pre-/post-drug administration as well as an effect of drug type.
There were also signiﬁcant effects of pre-/post-drug administra-
tion, stimulation frequency and a signiﬁcant interaction between
these effects. Post-hoc a two-way ANOVA was carried out on each
stimulation frequency to determine whether the effects of psilocin
administration were observed at speciﬁc frequencies. The Bonfer-
roni technique was used to adjust the a level for multiple
Fig. 2. Changes in BOLD signal magnitude in brain regions identiﬁed in Fig. 1. (AeD) Time series changes in the four brain regions showing BOLD activation/deactivation. Dotted
lines represent raw traces from individual animals that received a 2 mg/kg dose of psilocin, solid line is the mean of these animals. Blue and red lines represent the mean signal
changes from animals that received vehicle or 0.03 mg/kg psilocin, respectively, for comparison. The average traces for these groups have been low pass ﬁltered to improve clarity.
(EeH) Percentage change in BOLD signal magnitude relative to baseline for each of the four identiﬁed brain regions. The signal magnitude was calculated by averaging over the
period from 20 to 35 min after administration of 2 mg/kg psilocin (amygdala, cingulate cortex and somatosensory cortex) or 5e20 min after drug administration (hypothalamus).
Error bars represent standard error of the mean. MANOVA performed on the signal magnitude values (as summarised in EeH) revealed a signiﬁcant effect of drug dose (Hotelling's
Trace: df ¼ 8, 22; F ¼ 2.424; p ¼ 0.048). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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icant drug type pre-/post-drug administration effect was found at
all frequencies with psilocin treated animals showing a decrease inAUC of the LFP response after drug administration. This effect was
most pronounced at 20 and 40 Hz stimulation frequencies (Fig. 3D;
statistics summarised in Table 6).
Fig. 3. Treatment with 2 mg/kg psilocin increases the magnitude of the haemodynamic response to whisker stimulation in the somatosensory cortex. In a long stimulation
paradigm this was evident in the initial phase of the response where animals that received psilocin had an increased response amplitude (A). The magnitude of the neuronal
response in the somatosensory cortex to the same stimulation paradigm was unaltered (B). When shorter stimulations with multiple frequencies were applied this effect was
signiﬁcant only at 10 Hz (1C). Neuronal response magnitude was decreased after psilocin administration at high stimulation frequencies in the short stimulation, mixed frequency
paradigm (D). Data are mean ± SEM, N ¼ 6 for psilocin treatment, N ¼ 5 for vehicle treatment.
Table 2
Summary of statistical analyses of haemodynamic responses to 10 Hz, 16 s duration stimulation. * ¼ p < 0.05.
Parameter Factor df F p
Maximum of ﬁrst phase (0e8 s from stimulation onset) of CBF
response to 10 Hz, 16 s duration stimulation
Drug treatment 1,9 5.338 0.046*
Pre/post drug administration 1,9 6.632 0.030*
Drug treatment  Pre/post drug administration interaction 1,9 6.187 0.035*
Maximum of second phase (10e20 s from stimulation onset) of CBF
response to 10 Hz, 16 s duration stimulation
Drug treatment 1,9 0.033 0.861
Pre/post drug administration 1,9 0.137 0.720
Drug treatment  Pre/post drug administration interaction 1,9 2.037 0.187
Time to half maximum CBF response to 10 Hz, 16 s duration stimulation Drug treatment 1,9 0.198 0.667
Pre/post drug administration 1,9 0.031 0.863
Drug treatment  Pre/post drug administration interaction 1,9 0.131 0.726
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We have demonstrated that the BOLD signal changes observed
in response to psilocin administration are associated with alter-
ations in neurovascular coupling. Psilocin produced BOLD signal
changes in anatomically distinct regions including olfactory and
limbic systems, visual system, hippocampus, hypothalamus, pre-
limbic, cingulate and somatosensory cortices at a dose of 2 mg/kg.
BOLD signal changes did not occur in the same direction
throughout the brain, with signal increases and decreases observed
in different regions. Detailed investigation of CBF and neuronalresponses to whisker stimulation in the somatosensory cortex, a
region of psilocin-mediated decreased phMRI signal, demonstrated
stimulation frequency speciﬁc augmentation of the CBF response
by psilocin, accompanied by decreased neuronal response magni-
tudes; indicating modulation of the relationship between neuronal
activity and CBF. These ﬁndings suggest that psilocin alters neu-
rovascular coupling and that caution is required when making in-
ferences about drug effects on neuronal activity from changes
detected in neuroimaging signals.
The opposing directionality of LFP and CBF response changes in
the somatosensory cortex due to psilocin suggest altered
Table 3
Summary of statistical analyses of haemodynamic responses to mixed frequency, 2 s duration stimulation.
Parameter Factor df F p
Maximum CBF response to mixed frequency, 2 s duration stimulation Drug treatment 1,9 2.787 0.129
Pre/post drug administration 1,9 0.524 0.488
Drug treatment  Pre/post drug administration interaction 1,9 3.110 0.112
Stimulation frequency 5,45 1.207 0.321
Stimulation frequency  drug treatment interaction 5,45 2.115 0.081
Pre/post drug administration  frequency interaction 5,45 1.965 1.02
Pre/post drug administration  frequency  drug treatment interaction 5,45 1.866 0.119
Time to half maximum CBF response to mixed frequency, 2 s
duration stimulation
Drug treatment 1,9 1.314 0.281
Pre/post drug administration 1,9 1.029 0.337
Drug treatment  Pre/post drug administration interaction 1,9 1.200 0.302
Stimulation frequency 5,45 1.176 0.336
Stimulation frequency  drug treatment interaction 5,45 0.723 0.610
Pre/post drug administration  frequency interaction 5,45 1.498 0.209
Pre/post drug administration  frequency  drug treatment interaction 5,45 1.800 0.132
Analysis of 10 Hz CBF response data only Drug treatment 1,9 5.462 0.044*
Pre/post drug administration 1,9 3.359 0.100
Drug treatment  Pre/post drug administration interaction 1,9 5.125 0.050*
*¼p<0.05.
Table 4
Summary of statistical analyses of haemodynamic responses to 30 s increased CO2 concentration.
Parameter Factor df F p
Maximum CBF response to 30 s increased CO2 concentration Drug treatment 1,9 2.754 0.131
Pre/post drug administration 1,9 2.805 0.128
Drug treatment  Pre/post drug administration interaction 1,9 2.940 0.121
Fig. 4. Average neuronal responses to long, 16 s duration, 10 Hz whisker stimulation were not signiﬁcantly altered by administration of psilocin. Black lines show response means,
coloured bands represent SEM, N¼ 6 for psilocin treatment, N ¼ 5 for vehicle treatment. (A) The average response to the ﬁrst pulse in the stimulation train. (B) The average response
to all subsequent pulses in the train.
Table 5
Summary of statistical analyses of neuronal response magnitudes to 10 Hz, 16 s duration stimulation.
Stimulation frequency Factor df F p
10 Hz, 16 s stimulation Drug treatment 1,9 0.117 0.740
Pre/post drug administration 1,9 0.136 0.721
Drug treatment  Pre/post drug administration interaction 1,9 0.172 0.688
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BOLD-phMRI changes. The unaltered CBF responses to hypercapnia
challenge indicate that vascular reactivity was unaffected by
administration of psilocin (Rostrup et al., 1994). 5-HT2A receptors
are also expressed on both pyramidal cells (Willins et al., 1997) andinhibitory interneurons (Andrade, 2011; Puig and Gulledge, 2011)
suggesting that agonism of this receptor can have both excitatory
and inhibitory effects on downstream neuronal signalling. Cortical
inhibitory interneurons are capable of producing both vasodilation
and vasoconstriction (Cauli et al., 2004), providing a mechanism by
Table 6
Summary of statistical analyses of neuronal response magnitudes to mixed frequency, 2 s duration stimulation. * ¼ p < 0.0083.
Stimulation frequency Factor df F p
Mixed frequency, 2 s stimulation Drug treatment 1,9 30.539 <0.001*
Pre/post drug administration 1,9 48.122 <0.001*
Drug treatment  Pre/post drug administration interaction 1,9 111.839 <0.001*
Stimulation frequency 1,9 3631.889 <0.001*
Stimulation frequency  drug treatment interaction 5,45 50.504 <0.001*
Pre/post drug administration  frequency interaction 5,45 21.432 <0.001*
Pre/post drug administration  frequency  drug treatment interaction 5,45 136.091 <0.001*
1 Hz Drug treatment 1,9 2.009 0.187
Pre/post drug administration 1,9 15.051 0.003*
Drug treatment  Pre/post drug administration interaction 1,9 44.132 <0.001*
2 Hz Drug treatment 1,9 1.983 0.189
Pre/post drug administration 1,9 80.495 <0.001*
Drug treatment  Pre/post drug administration interaction 1,9 39.832 <0.001*
5 Hz Drug treatment 1,9 2.556 0.141
Pre/post drug administration 1,9 157.101 <0.001*
Drug treatment  Pre/post drug administration interaction 1,9 14.051 0.004*
10 Hz Drug treatment 1,9 0.458 0.514
Pre/post drug administration 1,9 256.354 <0.001*
Drug treatment  Pre/post drug administration interaction 1,9 33.898 <0.001*
20 Hz Drug treatment 1,9 37.478 <0.001*
Pre/post drug administration 1,9 3.610 0.087
Drug treatment  Pre/post drug administration interaction 1,9 88.602 <0.001*
40 Hz Drug treatment 1,9 69.494 <0.001*
Pre/post drug administration 1,9 29.415 <0.001*
Drug treatment  Pre/post drug administration interaction 1,9 192.861 <0.001*
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increased CBF. The linearity of the neurovascular response to
whisker stimulation has also been proposed to be dependent on
changes in the background balance of inhibition and excitation in
the brain (Buzsaki et al., 2007; Lauritzen et al., 2012), providing
additional means by which neurovascular coupling may be altered
by psilocin. The role of extra-cortical effects of psilocin on other
receptor subtypes in modulating the somatosensory response to
stimulation cannot be ruled out. For instance, the locus coeruleus
(LC) modulates CBF responses to whisker stimulation (Toussay
et al., 2013) and LC activity is known to be inhibited by
2,5-dimethoxy-4-iodoamphetamine (DOI), another non-selective
5-HT2A receptor agonist (Szabo and Blier, 2001). In addition, Fig. 3
shows that neuronal response to whisker stimulation at 40 Hz
increased over time in vehicle-treated controls. The directionality
of this effect is opposite to that found in the psilocin group. We are
unsure as to why this occurred, but it could be due to an effect of
anaesthetic depth varying over time or the effects of the vehicle,
tartaric acid. Since the change is in the opposite direction to that
induced by psilocin, it is possible that the changes we observed in
the psilocin group are being partially masked by this effect.
Recent work by Riga et al. (2014) investigated the neuronal and
fMRI signal effects of the 5-HT2A receptor agonist and hallucinogen
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), also in rats. In
agreement with the present ﬁndings they report a mixed pattern of
positive and negative BOLD signal changes in the brain, with
widespread areas of decreased BOLD signal occurring in sensory
cortex and subcortical BOLD signal increases (e.g. in hippocampus).
Riga et al. also showed reduced low frequency (0.15e4 Hz) oscil-
lations and increased pyramidal spiking activity associated with
decreased BOLD signal in medial prefrontal cortex following 5-
MeO-DMT administration. Against a background of reduced
neuronal oscillatory power in this ‘delta’ range, haemodynamic
response signals have been shown elsewhere to increase (Niessing
et al., 2005), providing an additional explanation for the enhance-
ment of stimulus-evoked haemodynamic responses observed herefollowing psilocin treatment.
Psilocin has both on- and off-target actions that may be
important for the interpretation of the results reported here.
Although there is strong evidence that the hallucinogenic effects of
psilocin are associated with 5-HT2A receptor activation (Quednow
et al., 2012; Halberstadt, 2015), the indirect nature of using hae-
modynamic neuroimaging signals as proxy measures for neuronal
activity make off-target effects, including non-hallucinogenic and
peripheral actions mediated by other receptor subtypes, an
important consideration. For example, psilocin has effects at most
5-HT receptor subtypes and also some dopamine receptors (e.g. see
Ray, 2010). In particular, the effects of psilocin on 5-HT1B/1D re-
ceptors, which are expressed on cerebral vasculature, may have a
direct ‘non-neuronal’ role in mediating haemodynamics. These off-
target effects could contribute to the changes in neural-
haemodynamic coupling observed here, and would again limit
the extent to which pharmacological neuroimaging readouts could
be interpreted as indicating increases or decreases in neuronal
activity.
The ﬁndings presented here are particularly relevant to situa-
tions where alterations in brain responses to sensory (e.g. visual,
auditory) stimulation are being investigated using neuroimaging,
as they demonstrate that serotonergic manipulations may alter the
relationship of BOLD signal changes to neuronal activity. To
exemplify, in isolation, our haemodynamic (i.e. neuroimaging) data
suggests that psilocin increases the magnitude of cortical responses
to sensory stimulation (Fig. 3A). In fact, our concurrent measure-
ment of neuronal response magnitudes suggests that if anything,
the opposite is true. Furthermore, these ﬁndings may have impli-
cations for neuroimaging studies in clinical cohorts where seroto-
nergic anomalies are known to exist (Rive et al., 2013). Alterations
of BOLD responses to stimulation in conjunction with pharmaco-
logical serotonin manipulations, such as with selective serotonin
reuptake inhibitors (SSRIs), have been documented in human
subjects (Klomp et al., 2013; Rive et al., 2013; Windischberger et al.,
2010) and our ﬁndings, based on concurrent measurement of
A. Spain et al. / Neuropharmacology 99 (2015) 210e220218neuronal and CBF changes underlying BOLD signals, demonstrate
why caution should be exercised in the interpretation of such
ﬁndings. Speciﬁcally, many interpretations of BOLD-fMRI signal
changes assume a monotonic relationship between evoked
neuronal and haemodynamic response magnitudes, something we
have here demonstrated to be altered by psilocin administration.
Furthermore, the alteration in neurovascular coupling we report
heremight explain, in part, the apparent discrepancy between fMRI
and PET ﬁndings of decreased CBF (Carhart-Harris et al., 2012a) and
increased glucose metabolism (Gouzoulis-Mayfrank et al., 1999;
Vollenweider et al., 1997) in human studies with psilocybin and
related drugs. Although it is widely assumed that neuronal activity,
glucose metabolism, cerebral blood ﬂow and fMRI BOLD signals
increase (or decrease) in tandem, this assumption has only been
extensively tested in conditions of sensory stimulus-induced acti-
vation change (and where caveats have been found): physiological
investigations in preclinical models will continue to be important
for detailing these relationships in pharmacological neuroimaging
contexts.
We have shown that the anatomical areas affected by psilocin in
the rat are congruent with those affected in the human brain
(Carhart-Harris et al., 2012a). The direction of our observed changes
in the rat is not, however, entirely consistent with those observed in
humans. In humans, BOLD signals were uniformly decreased in
response to psilocin administration, while BOLD signals in rat were
observed to increase as well as decrease, depending on the
anatomical location. The divergence in direction of signal change
may reﬂect either an interspecies difference in the effects of the
drug or the larger effective dose used in our study compared to that
of Carhart-Harris and colleagues (Carhart-Harris et al., 2012a)
(2 mg/kg vs. 2 mg/total body weight, respectively). The absence of
changes observed at 0.03 mg/kg in our study may be attributable to
interspecies differences between rats and humans. The dose of
0.03 mg/kg was calculated to be equivalent to the dose used by
Carhart-Harris and colleagues (2 mg/subject in their study divided
by our assumed 70 kg bodyweight per subject). Without scaling for
interspecies pharmacokinetic differences, however, there may not
be direct concordance between the two doses (Boxenbaum, 1982;
Lin, 1998).
Another important difference between our work and previous
human studies is the use of anaesthesia. Although methods to ac-
quire neuronal and haemodynamic data in awake animals have
been developed in our laboratory and elsewhere (C. Martin et al.,
2013; C.J. Martin et al., 2013; Takuwa et al., 2009), anaesthesia re-
mains important to enable invasive and concurrent measurement
of neuronal and haemodynamic data, especially in the context of
drug treatments like psilocin which are well-known for eliciting
head-twitch responses (Corne and Pickering, 1967). Anaesthetics,
including isoﬂurane as used in this study (the most popular choice
for preclinical phMRI research (Haensel et al., 2015)), are known
modulators of haemodynamic responses (Austin et al., 2005;
Martin et al., 2006; Tsurugizawa et al., 2010). Our experimental
design, which included within-subjects measurement of the effects
of psilocin, will to some extent mitigate against this as a con-
founding factor as animal anaesthesia levels were constant
throughout the pre- and post-drug conditions. The observation of
CBF responses to stimulation under anaesthesia even in vehicle
treated control animals as well as prior to drug administration also
suggests that this effect did not obscure CBF responses in this study.
This is consistent with data from previous work (Franceschini et al.,
2010; Masamoto et al., 2009; Sicard and Duong, 2005), which
shows that under isoﬂurane anaesthesia, capacity for blood ﬂow
changes in response to neuronal activation remains. The effects of
isoﬂurane on neurovascular coupling have also been demonstrated
to be comparable to those of other anaesthetics (Franceschini et al.,2010). As a result we are conﬁdent that the effects of isoﬂurane on
the results obtained in this study are small and were further
minimised by using the lowest necessary dose of isoﬂurane for
anaesthesia during experimental manipulations. Isoﬂurane is also
known to have a variety of neuronal effects (Haensel et al., 2015),
among these, it is known to increase permeability of GABAA re-
ceptors to chloride. This effect could be relevant to the current
study given the location of 5-HT2A receptors on GABAergic neurons,
however we did not ﬁnd psilocin related alterations in the neuronal
responses to whisker stimulation suggesting that any such effects
were minimal. It has been suggested that the sedative dexmede-
tomidine could provide an alternate, ‘compromise’ means of
avoiding the challenges of both general anaesthesia and awake
rodent studies (Weber et al., 2006). However, recent research has
demonstrated this drug to have a range of vascular, neuronal and
neurovascular actions (Fukuda et al., 2013) and as such was judged
to be less suitable for the present study.
In conclusion, psilocin induced alterations in neurovascular
coupling have implications for the interpretation of BOLD-phMRI
based investigation of psilocin, and possibly other 5-HT agonists,
as well as underlining the general need for caution in interpreting
fMRI studies in the context of neuropharmacological manipulations
(Shih et al., 2009). Determining a plausible mechanism of action for
this effect is necessary to progress research using such drugs.
phMRI studies in human subjects are important in this endeavour,
but additional studies will be necessary to connect the haemody-
namic readouts provided by such non-invasive neuroimaging
methods to better validated makers of neuronal activity, such as
those provided by experimental animal studies. More generally, we
suggest that such research is increasingly needed to underpin
interpretation of non-invasive (haemodynamic) functional imaging
studies of drug action in the human brain.
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